May 20, 2014
Jeffrey S. Mogil, Ph.D., E.P. Taylor Professor of Pain Studies, McGill University
Many are frustrated with the lack of translational progress in the pain field, in which huge gains in basic science knowledge obtained using animal models have not led to the development of many novel and clinically effective compounds. A careful reexamination of animal models of pain is therefore warranted. This course will describe the current implementation of animal models of pain, discuss a wide range of modulatory factors affecting data obtained within them, lay out the case for the replacement of current models by more sophisticated ones, and describe progress toward that goal.
Topics to be Covered:
- Classical models of acute, tonic and chronic pain
- Limitations of these classical models
- Refinement of classical models via a consideration of modulatory factors
(sex, genetics, testing environment, social modulation)
- Development of new animal models (e.g., operant methods, spontaneous behaviors)
Shaukat Ali, Ph.D., Technical Support Manager, BASF Corp.
Wantanee Phuapradit, Ph.D., Executive Vice President, Research & Development, Kashiv Pharma
Lipa Shah, Ph.D., Principal Scientist, Chemical and Pharmaceutical Profiling, Novartis Institutes for BioMedical Research, Inc.
Michael Perlman, Ph.D., Senior Scientist II, Biopharmaceutics and Physicochemical Profiling, Takeda Pharmaceuticals
Salin Gupta Patel, Ph.D., Associate Principal Scientist, Nanoparticles Technology Development Team Lead, Merck Research Labs
A significant number of new chemical entities (NCEs) are practically insoluble and thus, the industry is struggling to find solutions by adapting the non-conventional innovative and cost effective technologies in development of these molecules. This workshop will be aimed at understanding the significance of nanotechnology in formulation development and its role leading to enhance solubility and bioavailability of drug candidates.
Topics to be Covered:
- Amorphous dispersions and polymeric nanoparticulates
- Liquid dispersions, especially, lipid and surfactant based self emulsifying and nano-emulsifying systems (SEDDS/SNEDDS)
- Excipients’ role in design of robust dispersive systems and maintaining supersaturation
- Effects of particle size on API stability and performance
- Factors influencing the bioavailability of dosages
6:00-9:00 pm (Dinner)
Jeffrey E. Green, M.D., Chief, Transgenic Oncogenesis and Genomics Section, Laboratory of Cancer Biology and Genetics, National Cancer Institute
Zoë Weaver Ohler, PH.D., Principal Scientist, Preclinical Evaluation Team Leader, Center for Advanced Preclinical Research, Frederick National Laboratory for Cancer Research (NCI)
Neal Goodwin, Ph.D., Vice President Corporate Research Development, Champions Oncology, Inc.
Bruce R. Zetter, Ph.D., Charles Nowiszewski Professor of Cancer Biology, Department of Surgery, Harvard Medical School
Metastasis is the primary cause of patient mortality from cancer. This course will present methods that are used to study metastases in vivo using genetically-engineered mouse (GEM) models, standard xenografts, and patient derived xenografts to elucidate mechanisms controlling metastatic spread and therapeutic strategies using these preclinical models. Techniques used to disseminate tumors at metastatic sites and assess metastatic growth in vivo will be discussed, including tail vein and intracardiac injection, ex vivo pulmonary metastasis assay, luciferase imaging, and other non-invasive imaging modalities. Examples of specific topics to be covered include:
• Approaches to studying metastases in mice
• Strategies for experimental design with metastatic models
• Metastatic breast cancer models
• Metastatic ovarian cancer models (GEM and orthotopic)
• Melanoma metastatic models (orthotopic)
• PDX metastatic models
May 22, 2014
6:30-9:30 pm (Dinner)
Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center
Geoffrey A. Bartholomeusz, Ph.D., Assistant Professor and Director of the siRNA Core Facility, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Lesley Mathews Griner, Ph.D., Research Scientist, Biomolecular Screening and Profiling/Probe Development Group, National Center for Advancing Translational Sciences, NIH
Pierre Alexandre-Vidi, Ph.D., Post-doctoral Fellow, Department of Basic Medical Sciences, Purdue University
The course will provide an overview of the various 3D cell culture models available, their strengths and weaknesses, and where and how these models are being used, specifically for oncology research. The instructors will share their experiences on how they tested and evaluated various cell culture reagents and growth matrices, what worked and what didn’t and what you need to consider when setting up low and high throughput screening experiments using 3D cell cultures in your lab. The challenges working with 3D cell cultures, from experimental design to data analysis will be discussed.
*Separate registration required